Key result
Non-selective beta-blockers, particularly nadolol, significantly reduce the risk of adverse cardiac events and are recommended as first-line therapy across Long QT Syndrome subtypes 1, 2, and 3.
Why the study?
Given the high rate of adverse cardiac events or sudden cardiac death in LQTS, this review sought to highlight the genotype-specific treatment consensus in beta-blocker therapy for subtypes 1-3.
Do beta-blockers reduce adverse cardiac events in patients with Long QT Syndrome subtypes 1-3?
Systematic Review
Do beta-blockers reduce adverse cardiac events in patients with Long QT Syndrome subtypes 1-3?
This systematic review confirms that non-selective beta-blockers, particularly nadolol, are highly effective in reducing adverse cardiac events across the most common Long QT Syndrome subtypes (1-3).
Nadolol preferred first-line for LQTS 1-3; confirms non-selective beta-blockers reduce events across subtypes.
Long QT syndrome (LQTS) is one of the most common inherited cardiac channelopathies with a prevalence of 1:2000. The condition can be congenital or acquired with 15 recognized genotypes; the most common subtypes are LQTS 1, 2, and 3 making up to 85%-90% of the cases. LQTS is characterized by delayed ventricular cardiomyocyte repolarization manifesting on the surface electrocardiogram (EKG) by a prolonged corrected QT (QTc) interval. The mainstay of treatment for this condition involves in part or combination medical therapy via β-blockers as first-line (or other anti-arrhythmic), left cardiac sympathectomy, or implantable cardiac defibrillator placement. Given the high rate of adverse cardiac events (ACE) or sudden cardiac death (SCD) in this population of patients with this disease, this review seeks to highlight the genotype-specific treatment consensus in β-blocker therapy of the most common subtypes. A database search of PubMed, PMC, and Medline was conducted to ascertain the most recent data in the last five years on the management of LQTS types 1-3 and the role of β-blockers in reducing ACE in these types. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were adhered to in the study selection, and selected studies focused on humans, written in the English Language, and within the last five years of LQTS subtypes 1, 2, and 3. Eleven relevant studies were selected after considering inclusion criteria, exclusion criteria, and quality appraisal within the last five years, focusing on β-blocker selection directed based on the subtypes of LQTS. Two meta-analyses, one cohort study, and eight reviews provided significant data that non-selective β-blockers unequivocally are of benefit in these LQTS types. Summary of findings suggested nadolol followed by propranolol yields the best results in LQTS 1, while nadolol would yield the best effect in LQTS 2 and 3.
No takes yet. Share an insight, caveat, or question.
Went et al. (2021) conducted a systematic review in Long QT Syndrome (LQTS) subtypes 1, 2, and 3. Beta-blockers vs. Untreated or other beta-blockers was evaluated on Adverse cardiac events (ACE) and sudden cardiac death (SCD). Non-selective beta-blockers, particularly nadolol, significantly reduce the risk of adverse cardiac events and are recommended as first-line therapy across Long QT Syndrome subtypes 1, 2, and 3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: